Ana Riquelme
View from the Top
Ana Riquelme
Executive Director
AMID
Ana Riquelme exposes the contributions of AMID to the medical device sector and how the member companies work to strengthen the healthcare sector
Melissa Rosales
View from the Top
Melissa Rosales
Director General
RM Pharma
Melissa Rosales explains how volunteering for a clinical research study gives patients options to treat their illness
avon_magdalenaferreira
View from the Top
Magdalena Ferreira-Lamas
Vice President and General Manager for the Group of North Latin American Markets (NoLA)
Avon
Avon is the fifth-largest beauty company in the world. Avon’s brands include: ANEW, Avon Color, Avon Care, Skin so Soft and Advance Techniques.
Analysis healthcare investment
Analysis
While Mexico’s chronic disease epidemic continues unabated, new hurdles have arisen. The administration change brought with it a new vision to…
Wellmedic 1
Spotlight
Wellmedic Health Centers is a pioneering co-working and networking platform for doctors.
Hospitals and Care Providers
Infographic
IMSS is the main health insurance provider in Mexico, covering 29.5 percent of the population
Generics
Roundtable
Gurulinga Konanur
Gurulinga Konanur
Director General of Hetero Mexico

There are few API manufacturers in Mexico. As a result, we hold strong ground in Mexico. The quality of a medication relies entirely on the quality of the API. Developing an API requires significantly more investment in R&D than in manufacturing of the finished product. We invest heavily in R&D and we often begin planning them over 10 years before they go off patent. This helps us to offer products to clients at a much more advanced or early stage of product development. We see the biggest competition coming from Asian companies that offer their products at a low price, but they lack great services and speed to reach the market. Hetero has a 500ha chemical complex in Vizag, India that manufactures 24/7, which allows us to offer a high volume of high-quality products at affordable costs.

Stronger regulations on generics production, along with high costs of patent medications, have led to a boom in the Mexican generics market
Liomont Ocoyoacac
Insight
José Díaz
Executive Director
Micro Pharmaceuticals México
The constant price war and the sector’s sustained and relevant market growth have increased the attractiveness of participating in the private sector
Generics
Infographic
95 percent of medicines manufactured in Mexico are generics
Subscribe to MHR 2019